Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

COVID-19: JN.1 sub-variant has higher transmissibility and immune escape ability 

Spike mutation (S: L455S) is hallmark mutation of JN.1 sub-variant which significantly enhances its immune evasion capability enabling it to effectively evade Class 1 neutralizing antibodies. A study supports use of updated COVID-19 vaccines with spike protein to further protect the public.  

A surge in COVID-19 cases has been reported in many parts of the world. A new sub-variant JN.1 (BA.2.86.1.1) which evolved rapidly from BA.2.86 variant recently has been causing concern.  

JN.1 (BA.2.86.1.1) sub-variant possesses an additional spike mutation (S: L455S) compared to its precursor BA.2.86. This is hallmark mutation of JN.1 which significantly enhances its immune evasion capability enabling it to effectively evade Class 1 neutralizing antibodies. JN.1 also harbours three mutations in non-S proteins. Overall, JN.1 has increased transmissibility and immune escape ability1,2.  

COVID-19 vaccines have come a long way since pandemic and have been updated with reference to the spike protein to meet the challenges posed by newly emergent variants.  

A recent study suggests that an updated monovalent mRNA vaccine (XBB.1.5 MV) is effective in boosting serum virus-neutralization antibodies significantly against many sub-variants including against JN.1. This study supports the use the updated COVID-19 vaccines with spike protein to further protect the public3.  

On if JN.1 sub-variant presents an increased risk to public health relative to other currently circulating variants, CDC says there is no evidence4.  

*** 

References:  

  1. Yang S., et al 2023. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Preprint bioRxiv. Posted November 17, 2023. DOI: https://doi.org/10.1101/2023.11.13.566860  
  2. Kaku Y., et al 2023. Virological characteristics of the SARS-CoV-2 JN.1 variant. Preprint bioRxiv. Posted December 09, 2023. DOI: https://doi.org/10.1101/2023.12.08.570782  
  3. Wang Q. et al 2023. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Preprint bioRxiv. Posted December 06, 2023. DOI: https://doi.org/10.1101/2023.11.26.568730  
  4. Center for Disease Control. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC. Available at https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html   

*** 

Umesh Prasad
Umesh Prasad
Science journalist | Founder editor, Scientific European magazine

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Advances in Regeneration of Damaged Heart

Recent twin studies have shown novel ways of regenerating...

Humans and Viruses: A Brief History of Their Complex Relationship And Implications for COVID-19

Humans would not have existed without viruses because viral...

Hympavzi (marstacimab): New Treatment for Hemophilia

On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal...
- Advertisement -
93,065FansLike
47,315FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe